3. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)
Revenue growth past 5 years: 140.87%
Number of hedge fund holders: 31
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is a commercial-stage biopharmaceutical company focusing on the development and delivery of innovative therapies for patients suffering from debilitating cardiovascular and autoimmune diseases. Headquartered in London, UK, Kiniksa’s portfolio includes immune-modulating assets designed to address a range of inflammatory conditions. The company’s flagship product, ARCALYST, has been a key catalyst in cementing Kiniksa’s position in the biopharmaceutical industry. It is among the best UK growth stocks to buy.
ARCALYST is approved for the treatment of recurrent pericarditis, and since being launched in April 2021, it has seen significant adoption among healthcare providers. The success of the therapy has demonstrated Kiniksa’s commitment to addressing critical medical needs in the cardiovascular space.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) showcased robust sales for ARCALYST with a revenue growth of 79% year-over-year, reaching $417.0 million in 2024 and $122.5 million for Q4 2024. The robust figures highlight the strong market demand for ARCALYST and showcase the company’s effective commercial strategies and market position. The company has a cash position of $243.6 million as of December 31, 2024, a notable increase from $206.4 million a year earlier. Despite the strong performance of ARCALYST, the company reported a net loss of $8.9 million for Q4 and $43.2 million for the full year. Kiniksa, however, expects its current operating plan to remain cash flow positive on an annual basis, demonstrating prudent financial management and operational efficiency.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has provided optimistic guidance for 2025, projecting ARCALYST net product revenue between $560 million and $580 million. This forecast is reliant on the continued adoption of ARCALYST and the company’s strategic focus on expanding its product pipeline. The stock has a 3-year return of 89.48%, suggesting that it has experienced strong stock price appreciation over the past three years, also reflecting a substantial growth in shareholder value.
